Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
C N PereiraLaboratório de Síntese de Sistemas Heterocíclicos (LaSSH), Instituto de Física e Química (IFQ), Universidade Federal de Itajubá, Itajubá, Minas Gerais, Brazil.
L da Silva LaraLaboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
S da Costa LaneraLaboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
T Pérez de SouzaLaboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
M C de Souza PereiraLaboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
G L DeloguDepartment of Live and Environmental Sciences, University of Cagliari, Cittadella Universitaria, Monserrato, Italy.
M Silva Dos SantosLaboratório de Síntese de Sistemas Heterocíclicos (LaSSH), Instituto de Física e Química (IFQ), Universidade Federal de Itajubá, Itajubá, Minas Gerais, Brazil.ORCID 0000-0002-1075-9059
M J MatosDepartamento de Química Orgánica, Facultade de Farmacia, Universidade Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0002-3470-8299
Funding
Conselho Nacional de Desenvolvimento Científico e Tecnológico 404212/2023-9Conselho Nacional de Desenvolvimento Científico e Tecnológico 441649/2024-6Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de Minas Gerais Projetos-CEX-APQ-01014-14Fundação Oswaldo Cruz, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E26/201.001/2022Fundação Oswaldo Cruz, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/202.409/2021Fundação Oswaldo Cruz, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/210.613/2023Xunta da Galicia ED431B 2025/15
6 · The paper itself
Abstract
Chagas disease urgently requires the development of new, safe, and effective therapies. We evaluated a series of 6-hydroxy-3-aryl/heteroarylcoumarin derivatives against Trypanosoma cruzi to identify candidates with multistage activity. Our screening revealed that derivatives 1c (2-pyridyl) and 1f (2,3-dihydrobenzo[b][1,4]dioxine) are highly selective chemotypes toward trypomastigotes over Vero cells (SI = 549.45 and > 625, respectively), demonstrating submicromolar potency (IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exploring 6-Hydroxy-3-Aryl/Heteroarylcoumarins as Promising Candidates Against Trypanosoma cruzi. · full record | OpenQuestion